Vanda Pharmaceuticals
VNDA
171 hedge funds and large institutions have $319M invested in Vanda Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 63 increasing their positions, 38 reducing their positions, and 29 closing their positions.
448% more call options, than puts
Call options by funds: $5.8M | Put options by funds: $1.06M
72% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 29
66% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 38
12% more funds holding
Funds holding: 153 → 171 (+18)
7.32% more ownership
Funds ownership: 70.89% → 78.21% (+7.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
14% less capital invested
Capital invested by funds: $369M → $319M (-$49.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$13.5M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$7.53M |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$5.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$4.88M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$4.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$4.74M |
| 2 |
BlackRock
New York
|
-$3.84M |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$2.83M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.67M |
| 5 |
JF
Jump Financial
Chicago,
Illinois
|
-$2.12M |
VNDA Hedge Fund Activity: Q1 2026 in Review
171 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q1 2026, worth a combined $319M — down 14% from $369M a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new VNDA positions and 29 closed out — a net gain of 21 holders — while 63 added to existing stakes and 38 trimmed.
The largest buyer was State Street, adding an estimated $13.5M. The largest seller was Acadian Asset Management, cutting an estimated $4.74M.
- 171 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q1 2026, up from 153 in Q4 2025.
- Funds reported $319M of Vanda Pharmaceuticals stock for Q1 2026, down 14% quarter-over-quarter.
- 50 funds opened new Vanda Pharmaceuticals positions in Q1 2026 and 29 closed out, a net change of +21 holders.
- The largest Vanda Pharmaceuticals buyer in Q1 2026 was State Street, an estimated $13.5M added.
- The largest Vanda Pharmaceuticals seller in Q1 2026 was Acadian Asset Management, an estimated $4.74M sold.
Based on aggregated 13F filings for Q1 2026.